• Researchers are studying semaglutide, used in Novo Nordisk’s GLP 1 therapies, for its potential to reduce heavy drinking in patients with alcohol use disorder.
• Novo Nordisk and Lexicon Pharmaceuticals have started a Phase 1 trial of LX9851, a new obesity and metabolic disorder drug candidate.
• These developments suggest possible expansion of Novo Nordisk’s treatment areas beyond diabetes and obesity.

For investors tracking NYSE:NVO, these clinical moves arrive as the stock trades at $44.87, with a 9.0% gain over the past week and 21.3% over the past month. Over longer periods the picture is mixed, with a 14.4% decline year to date and a 30.1% decline over 1 year, but a 26.3% gain over 5 years.

Semaglutide’s potential role in alcohol use disorder and the early stage work on LX9851 could, if successful, broaden Novo Nordisk’s potential revenue sources and therapeutic reach. Readers may want to track how these programs progress through clinical stages and how the company prioritises them within its wider pipeline.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

For Novo Nordisk, the semaglutide alcohol use disorder data and the Lexicon partnership both speak to how the company is trying to widen its GLP 1 franchise while competition in diabetes and obesity intensifies from Eli Lilly, Pfizer and others. Alcohol use disorder would represent a new treatment area that still leans on an existing active ingredient, which can be attractive from a development and commercial perspective if regulators eventually approve such a use. The LX9851 Phase 1 trial, backed by up to US$1b in potential payments to Lexicon, suggests Novo Nordisk is also looking beyond semaglutide to future oral obesity and metabolic drugs, potentially diversifying its pipeline mix. For you as an investor, these moves sit against a backdrop of pricing pressure, regulatory scrutiny and valuation debates, so it can be helpful to view them less as immediate earnings drivers and more as early building blocks that might influence Novo Nordisk’s competitive position across several metabolic and neuropsychiatric markets over time.

The Risks and Rewards Investors Should Consider

• ⚠️ LX9851 is only in Phase 1, so there is clinical, regulatory and execution risk before any potential commercial payoff.
• ⚠️ Expanding semaglutide into alcohol use disorder could attract extra scrutiny on safety, pricing and reimbursement, especially given existing concerns around GLP 1 affordability.
• 🎁 Positive alcohol use disorder data and a new obesity candidate both support Novo Nordisk’s efforts to broaden its revenue base beyond current diabetes and obesity indications.
• 🎁 The Lexicon partnership structure, with milestones and royalties, allows Novo Nordisk to share risk and tap external R&D while preserving balance sheet flexibility.

What To Watch Going Forward

From here, focus on three things. First, follow any larger, controlled trials that further test semaglutide in alcohol use disorder and whether Novo Nordisk formally advances this into its pipeline. Second, track safety data, dosing and early efficacy signals from the LX9851 Phase 1 study through to its expected completion around early 2027. Third, watch how competitors such as Eli Lilly and Pfizer respond with their own metabolic and central nervous system programs targeting adjacent conditions. Together, these factors will help you gauge whether this partnership and indication expansion meaningfully reshapes Novo Nordisk’s long term treatment footprint or remains a set of smaller, supporting programs alongside its core GLP 1 obesity and diabetes franchises.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.